CU20200086A7 - Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes - Google Patents

Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Info

Publication number
CU20200086A7
CU20200086A7 CU2020000086A CU20200086A CU20200086A7 CU 20200086 A7 CU20200086 A7 CU 20200086A7 CU 2020000086 A CU2020000086 A CU 2020000086A CU 20200086 A CU20200086 A CU 20200086A CU 20200086 A7 CU20200086 A7 CU 20200086A7
Authority
CU
Cuba
Prior art keywords
drug
activity against
antimicrobial activity
resistant pathogens
against multi
Prior art date
Application number
CU2020000086A
Other languages
English (en)
Inventor
Perez Hilda Elisa Garay
Vivian Montero-Alejo
Rolando Perdomo-Morales
González Amanda Vázquez
Original Assignee
Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y Desarrollo De Medicamentos Cidem filed Critical Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority to CU2020000086A priority Critical patent/CU20200086A7/es
Priority to MX2023005925A priority patent/MX2023005925A/es
Priority to CN202180071094.XA priority patent/CN116406282A/zh
Priority to JP2023523524A priority patent/JP2024508205A/ja
Priority to EP21865361.6A priority patent/EP4249500A2/en
Priority to CA3199519A priority patent/CA3199519A1/en
Priority to PCT/CU2021/050011 priority patent/WO2022105948A2/es
Priority to US18/037,534 priority patent/US20240239849A1/en
Publication of CU20200086A7 publication Critical patent/CU20200086A7/es
Priority to CONC2023/0007878A priority patent/CO2023007878A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Insects & Arthropods (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención describe compuestos peptídicos sintéticos que combaten microorganismos patógenos de naturaleza bacteriana, y que presentan como microorganismos multirresistentes a antibióticos convencionales. Además, describe terapias de combinación que contienen dichos péptidos. Se describen composiciones farmacéuticas que comprenden a los compuestos peptídicos y sus combinaciones.</p>
CU2020000086A 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes CU20200086A7 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CU2020000086A CU20200086A7 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
MX2023005925A MX2023005925A (es) 2020-11-19 2021-11-18 Entidades peptidicas con actividad antimicrobiana frente a patogenos multi-drogoresistentes.
CN202180071094.XA CN116406282A (zh) 2020-11-19 2021-11-18 具有针对多药耐药性病原体的抗微生物活性的肽实体
JP2023523524A JP2024508205A (ja) 2020-11-19 2021-11-18 多剤耐性病原体に対する抗菌活性を有するペプチド実体
EP21865361.6A EP4249500A2 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
CA3199519A CA3199519A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
PCT/CU2021/050011 WO2022105948A2 (es) 2020-11-19 2021-11-18 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
US18/037,534 US20240239849A1 (en) 2020-11-19 2021-11-18 Peptide entities with antimicrobial activity against multi-drug resistant pathogens
CONC2023/0007878A CO2023007878A2 (es) 2020-11-19 2023-06-15 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000086A CU20200086A7 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Publications (1)

Publication Number Publication Date
CU20200086A7 true CU20200086A7 (es) 2022-06-06

Family

ID=80684162

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000086A CU20200086A7 (es) 2020-11-19 2020-11-19 Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes

Country Status (9)

Country Link
US (1) US20240239849A1 (es)
EP (1) EP4249500A2 (es)
JP (1) JP2024508205A (es)
CN (1) CN116406282A (es)
CA (1) CA3199519A1 (es)
CO (1) CO2023007878A2 (es)
CU (1) CU20200086A7 (es)
MX (1) MX2023005925A (es)
WO (1) WO2022105948A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117756904B (zh) * 2023-12-22 2024-05-24 潍坊医学院 一种订书肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6940796A (en) * 1995-08-23 1997-03-19 University Of British Columbia, The Antimicrobial cationic peptides and methods of screening for the same
CU24073B1 (es) 2011-12-27 2015-01-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem COMPOSICIÓN A PARTIR DE EXTRACTO DE HEMOCITOS DE LANGOSTA PARA LA DETECCIÓN DE LIPOPOLISACÁRIDOS, PEPTIDOGLICANOS Y 1,3-ß-D-GLUCANOS
JP7253257B2 (ja) * 2017-05-11 2023-04-06 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー- ユーシーエルエー メディカル センター アルファコアヘリックスを有する抗微生物ペプチド

Also Published As

Publication number Publication date
CO2023007878A2 (es) 2023-07-21
US20240239849A1 (en) 2024-07-18
CN116406282A (zh) 2023-07-07
MX2023005925A (es) 2023-05-29
JP2024508205A (ja) 2024-02-26
EP4249500A2 (en) 2023-09-27
WO2022105948A2 (es) 2022-05-27
WO2022105948A3 (es) 2022-10-20
CA3199519A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CO2018011701A2 (es) Formulaciones de antibióticos glicopeptídicos estabilizados
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112019024264A2 (pt) Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
BR112015029367A8 (pt) combinação compreendendo oxazolidinonaquinolonas, seu uso, composição farmacêutica, e kit de partes
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
CU20200086A7 (es) Entidades peptídicas con actividad antimicrobiana frente a patógenos multi-drogoresistentes
EP3574900A8 (en) New applications of rifamycin-nitroimidazole coupling molecules
AR119025A1 (es) Composición que comprende un bacillus formador de biopelícula
EP3795169A4 (en) RECOMBINANT PROTEIN DERIVED FROM A BACTERIOPHAGE WITH ANTIMICROBIAL ACTIVITY AGAINST PATHOGENIC GRAM-NEGATIVE BACTERIA
WO2020102901A8 (en) Synthetic antibacterial compounds and uses thereof
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112022000041A2 (pt) Inibidores de detecção de quorum e / ou metabólitos pósbióticos e métodos relacionados
CO2021000147A2 (es) Composición agrícola
MX2021015961A (es) Moleculas novedosas.
MX2021014310A (es) Formulaciones de terlipressina.
CL2021003317A1 (es) Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula.
BR112012015154A2 (pt) &#34;combinação sinergética de protioconazol e metominostrobin.&#34;
BR112022012368A2 (pt) Composto, e, composição farmacêutica para o tratamento de doenças associadas a diacilglicerol aciltransferase 2
BR112013008037A2 (pt) compostos multivalentes como tratamento antibiótico
BR112021023169A2 (pt) Métodos e composições para fermentação bacteriana anaeróbica
EP3821903A4 (en) USING THE RECOMBINANT ANTIBACTERIAL ENZYME LYSSAP26 TO EFFECTIVELY KILL PATHOGENIC BACTERIA
BR112019003861A2 (pt) compostos contendo monoterpenoides / fenilpropanóides e métodos de sua fabricação e uso como tratamentos de sementes